Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
This study has been completed.
Sponsor:
Kos Pharmaceuticals
Information provided by:
Kos Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00080275
First received: March 25, 2004
Last updated: October 31, 2006
Last verified: October 2006
Tracking Information | |
---|---|
First Received Date ICMJE | March 25, 2004 |
Last Updated Date | October 31, 2006 |
Start Date ICMJE | March 2004 |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE | |
Original Primary Outcome Measures ICMJE | |
Change History | Complete list of historical versions of study NCT00080275 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE | |
Original Secondary Outcome Measures ICMJE | |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS) |
Official Title ICMJE | An Open-Label Evaluation of the Safety and Efficacy of a Combination of Niacin ER and Simvastatin in Patients With Dyslipidemia (OCEANS) |
Brief Summary | The purpose of this 24 week study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS) in subjects with elevated fat levels in their blood (dyslipidemia). At least 600 subjects with a similar medical condition will take part in this study. |
Detailed Description | Objectives: To evaluate the safety and efficacy of the combination product niacin ER and simvastatin (NS) in patients with primary type II dyslipidemia and to descriptively compare flushing rates between two Titration Schedules for NS. |
Study Type ICMJE | Interventional |
Study Phase | Phase 3 |
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE | Hypercholesterolemia |
Intervention ICMJE | Drug: Niacin Extended-Release and simvastatin Tablets |
Study Arm (s) | |
Publications * | |
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Completed |
Enrollment ICMJE | 600 |
Completion Date | |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 21 Years and older |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | |
Administrative Information | |
NCT Number ICMJE | NCT00080275 |
Other Study ID Numbers ICMJE | 019-02-03-CR, OCEANS |
Has Data Monitoring Committee | |
Responsible Party | |
Study Sponsor ICMJE | Kos Pharmaceuticals |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | Kos Pharmaceuticals |
Verification Date | October 2006 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |